

**IN THE SPECIFICATION:**

**Please insert the following paragraph before the first full paragraph of page 1:**

This application is a continuation of patent application Ser. No. 09/220,674, filed December 23, 1998, now abandoned, which is a continuation-in-part of patent application Ser. No. 08/997,803, filed December 24, 1997, now U.S. Pat. No. 6,057,126.

**Please replace the sixth full paragraph at lines 15 - 17 of page 4 with the following amended paragraph:**

Figure 5A shows the alignment of the predicted amino acid sequences of HEDG5 translation products of clones pC3-hedg5-3, pC3-hedg5#3.4, and pC3-hedg5#28 as set out in Figures 4A (~~SEQ ID NO:27~~), 4B (~~SEQ ID NO:28~~) and 4C (~~SEQ ID NO:28~~), respectively (amino acid sequence of clone pC3-hedg5-3 in Figure 4A: SEQ ID NO:14, amino acid sequence of clone pC3-hedg5#3.4 in Figure 4B: SEQ ID NO:27, and amino acid sequence of clone pC3-hedg5#28 in Figure 4C: SEQ ID NO: 28).

**Please replace the seventh full paragraph at lines 19 - 20 of page 4 with the following amended paragraph:**

Figure 5B shows the alignment of the amino acid sequence of murine edg-5 (MEDG-5: SEQ ID NO: 23) with the amino acid sequence of human edg-5 from the pC3-hEdg5#3.4 (HEDG-5: SEQ ID NO: 27).

**Please replace the eighth full paragraph at lines 22-23 of page 4 with the following amended paragraph:**

Figure 6 shows the functional response of the pC3-hedge5#3.4, pC3-hedg5-3 and pC3-hedg5#28 clones to anandamide and to LPA by activation of NF-kB production.

**IN THE DRAWINGS:**

Please replace figures 4A, 4B, and 4C with the attached substitute figures 4A, 4B, and 4C. The legend in Figure 4A itself has been amended to correct a typographical error.

**IN THE SEQUENCE LISTINGS:**

Please replace the previous sequence listing with the substitute sequence listings filed concurrently herewith.